CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
The Social Security Administration today announced actions to help parents enroll newborns in Trump Accounts, which are investment accounts for children under…
Headline
Sara Bode, M.D., pediatrician and medical director of School Health Services at Nationwide Children’s Hospital, and Carneshia Edwards, lead of the Kindergarten…
Headline
The AHA invites hospital leaders from organizations that care for children with medical complexities to join a roundtable for peer learning, collaboration and…
Headline
The Health Resources and Services Administration Maternal and Child Health Bureau has announced grant opportunities available supporting maternal and child…
Headline
President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization…
Headline
The AHA and other national health care groups sent a letter to members of the House and Senate appropriations committees, urging them to provide $1.…